Adversarially-validated entity intelligence on demand for the 301 monitored biopharma entities in the AimwellBio Federated Intelligence Network. Every claim cited to a public-source URL. Encrypted to your member vault. The first research artifact built around the adversarial-validation methodology.
Every AIMN:VERDICT now also carries a G1–G7 grade for use in dashboards, IC memos, and regulatory submissions. PROCEED · DELAY · KILL remains the canonical verdict; the grade adds confidence-and-impact resolution.
Citeline tracks trials. Cortellis tracks regulatory. AlphaSense indexes transcripts. Bloomberg shows financials. Expert networks charge $1,000/hour for qualitative depth. Five separate logins, five separate invoices, and at the end the analyst still has to assemble the verdict by hand.
Click a marker on /atlas. Streaming progress shows the engine reading PubMed, ClinicalTrials.gov, SEC EDGAR, FDA enforcement, and EMA EPAR in parallel. Within 90 seconds you receive a 2–3 page rendered verdict with every claim hyperlinked to its source. Re-run with deeper search at 4-iteration mode in 150–180 seconds.
Every verdict separates the entity's public narrative (what they claim in 10-K MD&A and IR materials) from the public record (what trials, filings, enforcement, and peer-reviewed literature actually contain). The variance between the two is the verdict. Methodology disclosed in full at /methodology.
After generation, the engine HEAD-checks every cited URL. If more than 10% fail to resolve, the verdict's confidence score drops to LOW with a yellow disclaimer. This is the institutional-credibility gate. It is what separates a verdict from generic AI search output. Incumbents do not ship this.
A reduced-fidelity sample of the verdict format is published for public review. Full verdicts are member-gated; this sample shows the structure, the citation discipline, and the variance-analysis layout. Marked SAMPLE — not a live production verdict.
Institutional partners do not buy black-box AI tooling. They buy methodology they can defend in a regulator's room. The full AIMN:VERDICT methodology is published openly at /methodology. Three pillars below.
The system prompt instructs the model to surface variance between public narrative and public record. This template is the brand IP. Available for member review on request — not generated content.
Post-generation, every cited URL is HEAD-checked against the public web. If >10% fail to resolve, the verdict's confidence score drops to LOW with a yellow disclaimer. Non-negotiable.
0–100 score driven by source coverage (PubMed depth, recent SEC filings, trial volume) and citation resolution rate. Visible on every verdict. Members trust the floor — they know which verdicts to act on and which to flag.
The Founding-Contributor tier finances the AIMN:VERDICT engineering build. After the 100-seat allotment, Founding pricing rises to $599 / $699 / $799 in subsequent waves. Reserve now.